#USA #biopharmaceuticals #Ibezapolstat #Staten Island #Acurx Pharmaceuticals

Acurx Pharmaceuticals Reports First Quarter 2026 Results and Business Updates

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP), a prominent late-stage biopharmaceutical company, has released significant details regarding its first-quarter results for 2026, as well as updates on its ongoing clinical initiatives on May 12, 2026. The company focuses on developing a novel class of antibiotics specifically aimed at combating resistant bacterial infections, such as Clostridioides difficile (CDI).

Key Developments

Patents Granted
One of the notable milestones for Acurx this quarter includes the recent patent approval by the United States Patent and Trademark Office (USPTO) for their DNA polymerase IIIC (pol IIIC) inhibitors, which extends until December 2039. This patent significantly enriches Acurx's extensive library of intellectual properties, including further patents that stretch out as far as 2042. Alongside this, a new patent awarded by the Korean Patent Office bolsters their international intellectual property protections.

Moreover, in March 2026, Acurx announced an innovative clinical trial program targeting recurrent CDI utilizing their breakthrough antibiotic candidate, Ibezapolstat (IBZ). The trial aims to potentially revolutionize treatment by combining two agents into one, supported by earlier Phase 2 results that indicated a 96% clinical cure rate in treating acute CDI without any recurrence, while protecting the gut microbiome. The upcoming trial begins with an open-label pilot study designed for up to 20 patients with a history of recurrent CDI.

Financial Performance
In terms of financial positioning, Acurx concluded the first quarter of 2026 with $9.3 million in cash, an increase from $7.6 million in the previous quarter. Throughout the period, the company successfully generated roughly $3.1 million in gross proceeds via their Equity Line of Credit.
Research and development expenditures saw a notable reduction, costing $0.3 million down from $0.6 million the prior year. Simultaneously, general and administrative costs dipped to $1.4 million compared to $1.6 million in Q1 of 2025. Acurx reported a net loss of $1.7 million—or $0.62 per diluted share—improving from a net loss of $2.1 million for the same period last year.

Clinical Trials and Future Aspirations

A pivotal objective in Acurx's strategy is advancing its clinical programs towards Phase 3 international trials. Excitingly, the FDA proposed a shift in its usual two-trial requirement for registration, which could shorten the timeline for clinical development. Given the recent discussions in the New England Journal of Medicine, Acurx expects this shift could greatly benefit their plans for broader CDI applications.

The anticipated Phase 3 registration trial for Ibezapolstat is contingent upon productive results from the initial studies. Should the trials exhibit favorable outcomes, Acurx aims to request FDA approval under the Limited Population Pathway for Antibacterial and Antifungal Drugs Guidance.

Acurx's progress is not limited to CDI; they are also launching clinical programs targeting other antibiotic-resistant infections. With steady advancements through both clinical and financial avenues, Acurx positions itself as a frontrunner in fighting difficult-to-treat bacterial pathogens.

Conclusion

As Acurx Pharmaceuticals prepares to navigate through 2026, it does so with a strengthened patent portfolio, improved financial stability, and an innovative approach to clinical trials that could reshape the future of antibiotic treatments for challenging infections. Investors and healthcare professionals alike await the outcomes of their ongoing clinical developments, anticipating them as potential game-changers in the biopharmaceutical landscape. For more information about their advancements, visit Acurx Pharmaceuticals.